Project Grant R01NS140370

Award Date 5/1/25
Completion Date 4/30/30
Dollars Obligated $771K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award of $2,814,824.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS), under the federal Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award supports a multi-year research initiative led by the Washington University to investigate the pathogenesis of cerebral small vessel disease (CSVD) and vascular contributions to dementia (VCID). The key objectives are to: 1) identify...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), provides $776,503 to The General Hospital Corporation (Massachusetts General Hospital) to investigate the role of perivascular inflammation and vascular remodeling in cerebral small vessel diseases (CSVD), which can lead to intracerebral hemorrhage. The project will leverage autopsy cases and mouse...
This $4,693,249 federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support the University of California, Los Angeles (UCLA) in defining the molecular spectrum of white matter vascular lesions that drive vascular cognitive impairment and dementia (VCID). The project aims to advance the mechanistic understanding of molecular...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,120,805.00 to the University of Illinois to investigate the impact of prior SARS-CoV-2 infection on the risk of vascular contributions to cognitive impairment and dementia (VCID). The key objectives of this 1-year grant are to: 1) determine how prior SARS-CoV-2 infection...
This federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), will fund a study on the impact of NOTCH3 mutations on cerebrovascular reactivity (CVR) in patients with CADASIL, a rare monogenic cause of stroke and vascular contributions to cognitive impairment and dementia (VCID). The $801,476 grant, awarded on Sep 30, 2024, will leverage the longitudinal CADASIL Consortium cohort to examine CVR, a measure of microvascular function,...
This federal Project Grant award of $1,008,977.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to understand human brain development and the origins of neurodevelopmental diseases, with a focus on studying recently-discovered neural progenitor cell types in the outer subventricular zone of the developing human cerebral...
This Project Grant award, valued at $2,398,590.00, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The research aims to investigate the role of alterations in brain microcirculation and capillary endothelial cell energetics in the development of vascular cognitive impairment and dementia (VCID), including in Alzheimer's disease (AD) and...
This $4,692,540 federal Project Grant from the National Institute on Aging (CFDA 93.866, Aging Research) aims to develop advanced MRI techniques to directly assess cerebral microvascular pulsatility on widely available 3T MRI systems. The project seeks to investigate the relationship between cerebral microvascular pulsatility and the global burden of cerebral small vessel disease (CSVD) as an MRI biomarker of brain parenchymal injury. The research will be conducted by Northwestern University...
This $5,949,022 federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports a collaborative research effort to identify novel therapeutic targets for treating cerebral amyloid angiopathy (CAA), a key contributor to Alzheimer's disease and related dementias (ADRD). The primary awardee, The Jackson Laboratory, is partnering with...
This $853,135 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA Program 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders, will support research to investigate the role of the complement C3a receptor in exacerbating acute post-ischemic brain injury and long-term neurological dysfunction following stroke. The key objectives are to: 1) Demonstrate that genetic inhibition of endothelial C3a receptor...

This Federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $770,502.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the mechanisms and functional impact of cerebral small vessel disease (CSVD). The award supports investigations into how mutations in the COL4A1 and COL4A2 genes regulate TGF-beta signaling and impact cerebrovascular function, with the goal of gaining a better understanding of the pathogenesis of CSVD and its links to vascular contributions to cognitive impairment and dementia (VCID). The research will utilize mouse models to perform intravital imaging of the cerebral vasculature, evaluate behavioral measures of cognitive impairment, and test hypotheses around the role of matrix metalloproteinases in CSVD progression. The project is expected to run from May 1, 2025 to April 30, 2030 and provide significant insights into the genetic and molecular underpinnings of both monogenic and idiopathic forms of CSVD.

Generated 5/13/25, 3:23 AM